Healthcare ❯Pharmaceuticals ❯Regulatory Affairs ❯FDA Approval

Donanemab

FDA Panel Recommends Approval of Promising Alzheimer's Drug Donanemab

Eli Lilly's new treatment shows potential in slowing cognitive decline but raises safety and accessibility concerns.